BARCELONA — Liraglutide, a once-daily investigational human glucagon-like peptide-1 analogue, achieved impressive reductions in multiple cardiovascular risk biomarkers in type 2 diabetes patients in a meta-analysis of six phase III randomized trials.
PREVIEW